Though a reduced frequency of CD8+ T cells against insulin but not unrelated islet or foreign antigens and preservation of C-peptide levels were observed over the course of the study, it remains unknown whether this treatment and other clinical trials based on insulin tolerization influenced the course of T1D and protected the residual β cells mass from the diabetogenic autoimmune response over time. This evidence concerns the gene INS and type 1 diabetes mellitus.